Viking Therapeutics finds itself at a critical juncture, balancing a robust financial position with the anticipation of pivotal clinical trial data. The biopharmaceutical company, specializing in metabolic and endocrine disorders, holds approximately $706 million in cash. This substantial war chest supports two ongoing Phase 3 studies, setting the stage for significant developments in the coming years.
Upcoming Milestones and Pipeline Focus
The core of Viking’s near-term strategy revolves around its VANQUISH clinical program for the subcutaneous drug candidate VK2735. This dual GLP-1/GIP receptor agonist is being evaluated in two large-scale trials.
The VANQUISH-1 study has enrolled roughly 4,650 participants with obesity, defined as a body mass index of at least 30, or 27 with weight-related comorbidities. This trial will run for 78 weeks. Its companion study, VANQUISH-2, is recruiting nearly 1,100 adults who are overweight or obese and have type 2 diabetes. The company anticipates completing enrollment for VANQUISH-2 in the first quarter of 2026. Top-line results from both studies are not expected until 2027, with data from VANQUISH-1 likely arriving in the first half of that year.
These future catalysts are underpinned by promising Phase 2 data. The VENTURE study demonstrated a mean weight reduction of up to 14.7% after 13 weeks of treatment with VK2735, with no observed plateau effect. Most adverse events were characterized as mild to moderate. These findings were recently published in a peer-reviewed medical journal.
Analyst Sentiment and Market Performance
Wall Street analysts have shown renewed interest in Viking’s prospects. On February 26, BTIG Research upgraded its rating on the stock to “Strong Buy.” Earlier in the month, on February 12, Morgan Stanley reaffirmed an “Overweight” rating alongside a $99 price target. In a notable revision, Zacks Research shifted its stance from “Strong Sell” to “Hold.”
Current consensus, as aggregated by MarketBeat, reflects a “Moderate Buy” rating. This is based on recommendations from four analysts advocating “Strong Buy,” five suggesting “Buy,” three advising “Hold,” and one issuing a “Sell.” The average price target among these firms stands at $87.80. Recently trading at $33.34 per share, the stock experienced a weekly decline of 3.25%, valuing the company at a market capitalization of approximately $3.83 billion.
Should investors sell immediately? Or is it worth buying Viking Therapeutics?
Expanding the Clinical Portfolio
Beyond its lead obesity program, Viking is advancing several other assets. The company completed enrollment in January 2026 for a study investigating a maintenance dose regimen for VK2735, with results anticipated in the third quarter of that year. Furthermore, an oral formulation of VK2735 is slated to enter Phase 3 trials for obesity also in Q3 2026.
Looking ahead to the first quarter of 2026, Viking plans to submit an Investigational New Drug (IND) application for a dual amylin and calcitonin receptor agonist (DACRA). This therapeutic approach is designed for patients unable to tolerate GLP-1-based therapies.
Concurrently, the company is conducting a Phase 2b study of VK2809 for the treatment of non-alcoholic steatohepatitis (NASH) and associated liver fibrosis.
Management Engagement and Path Forward
Viking’s executive team is scheduled to engage with the investment community at two key conferences in March. They will participate in the Leerink Partners Global Healthcare Conference in Miami from March 8-11, followed by the Jefferies Biotech on the Beach Summit, also in Miami, on March 10-11.
While the Phase 2 data solidifies VK2735 as a potentially competitive agent in the metabolic space, the definitive regulatory pathway hinges on the outcomes of the VANQUISH trials in 2027. The company’s substantial cash reserves provide the runway to reach these decisive milestones.
Ad
Viking Therapeutics Stock: Buy or Sell?! New Viking Therapeutics Analysis from March 3 delivers the answer:
The latest Viking Therapeutics figures speak for themselves: Urgent action needed for Viking Therapeutics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 3.
Viking Therapeutics: Buy or sell? Read more here...
